Yahoo Finance

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

TAMPA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Yahoo Finance

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Monthly Prescribing Reference

Exparel Gets Expanded Approval for Sciatic and Adductor Canal Nerve Blocks

In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...
Pharm Exec

FDA Approves Expanded Nerve Block Indications for Pacira BioSciences' Exparel

FDA expands indications for bupivacaine liposome injectable suspension (Exparel; Pacira BioSciences, Inc.) for use in adult patients as an adductor canal block and a sciatic nerve block in the ...
Monthly Prescribing Reference

Exparel Application Under Review for Sciatic and Femoral Nerve Blocks

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
Healio

Proximal sciatic nerve block reduced pain after MPFL reconstruction in pediatric patients

Please provide your email address to receive an email when new articles are posted on . Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block ...